EUDRACAP® colon – The world’s first functional ready-to-fill capsule for oral drug delivery to target the ileo-colonic region

EUDRACAP® colon is the world’s first ready-to-fill capsule available on the market to target the ileo-colonic region. It enables the development of new breakthrough oral drugs by solving formulation challenges for the increasing number of sensitive drug candidates.

Sensitive drug candidates, such as live biotherapeutics that target the microbiome, oral biologics, proteins and peptides, and nucleotides, are being developed for indications like diabetes, obesity, cancer, Parkinson’s and Alzheimer’s diseases.

EUDRACAP® colon brings together a range of key features and functionalities offered nowhere else on the market.

First, EUDRACAP® colon protects sensitive actives during the manufacturing process of the dosage form. The capsules can be used as functionalized ‘containers’ and therefore need no complex formulation development, which enables accelerated entry into clinical trials and faster drug commercialization.

Second, EUDRACAP® colon protects sensitive APIs against the acidic environment of the GI-tract and ensures that it can be transported to the ileo-colonic region.

Third, EUDRACAP® colon provides targeted drug delivery to the ileo-colonic region, helping to improve treatment efficiency.

EUDRACAP® colon allows the development of new breakthrough drugs using novel classes of APIs. The functionalized ready-to-fill capsules provide reliable protection of the API against gastric acid, enable the drug delivery to the desired target in the ileo-colonic region for optimal drug efficiency and can be easily filled using common automated capsule filling equipment.